DK3207035T3 - Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter - Google Patents
Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter Download PDFInfo
- Publication number
- DK3207035T3 DK3207035T3 DK15850314.4T DK15850314T DK3207035T3 DK 3207035 T3 DK3207035 T3 DK 3207035T3 DK 15850314 T DK15850314 T DK 15850314T DK 3207035 T3 DK3207035 T3 DK 3207035T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- compounds
- kinase activities
- egfr mutant
- mutant kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quick-Acting Or Multi-Walled Pipe Joints (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063394P | 2014-10-13 | 2014-10-13 | |
| PCT/KR2015/010784 WO2016060443A2 (en) | 2014-10-13 | 2015-10-13 | Compounds and compositions for modulating egfr mutant kinase activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3207035T3 true DK3207035T3 (da) | 2020-01-27 |
Family
ID=55654993
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15850314.4T DK3207035T3 (da) | 2014-10-13 | 2015-10-13 | Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter |
| DK19196713.2T DK3604294T3 (da) | 2014-10-13 | 2015-10-13 | Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter |
| DK21171619.6T DK3929190T3 (da) | 2014-10-13 | 2015-10-13 | Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19196713.2T DK3604294T3 (da) | 2014-10-13 | 2015-10-13 | Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter |
| DK21171619.6T DK3929190T3 (da) | 2014-10-13 | 2015-10-13 | Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9593098B2 (enExample) |
| EP (4) | EP4421069B1 (enExample) |
| JP (3) | JP6524221B2 (enExample) |
| KR (5) | KR20240074820A (enExample) |
| CN (2) | CN111686110B (enExample) |
| AU (1) | AU2015331166B2 (enExample) |
| BR (1) | BR112017007769B1 (enExample) |
| CA (1) | CA2962914C (enExample) |
| CY (2) | CY1122737T1 (enExample) |
| DK (3) | DK3207035T3 (enExample) |
| ES (3) | ES3009926T3 (enExample) |
| FI (2) | FI3929190T3 (enExample) |
| FR (1) | FR25C1021I1 (enExample) |
| HR (3) | HRP20200201T1 (enExample) |
| HU (4) | HUE054848T2 (enExample) |
| LT (4) | LT3207035T (enExample) |
| MX (3) | MX2017003181A (enExample) |
| NL (1) | NL301329I2 (enExample) |
| NO (1) | NO2025025I1 (enExample) |
| NZ (1) | NZ730012A (enExample) |
| PH (1) | PH12017500488A1 (enExample) |
| PL (3) | PL3929190T3 (enExample) |
| PT (3) | PT3604294T (enExample) |
| RS (3) | RS66529B1 (enExample) |
| RU (1) | RU2727700C2 (enExample) |
| SG (1) | SG11201701960XA (enExample) |
| SI (3) | SI3604294T1 (enExample) |
| SM (3) | SMT202500069T1 (enExample) |
| TW (2) | TWI730331B (enExample) |
| WO (1) | WO2016060443A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054848T2 (hu) * | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| KR20180105161A (ko) | 2016-01-07 | 2018-09-27 | 씨에스 파마테크 리미티드 | Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 |
| US10513509B2 (en) * | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| KR102030886B1 (ko) * | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| AU2018286221B2 (en) * | 2017-06-13 | 2021-02-25 | Beijing Adamadle Biotechnology Limited Liability Company | Aminopyrimidine compound, preparation method therefor and use thereof |
| MX2022008743A (es) | 2017-07-28 | 2023-02-02 | Yuhan Corp | Proceso mejorado para preparar derivados de aminopirimidina. |
| AU2018308039B2 (en) * | 2017-07-28 | 2022-04-14 | Yuhan Corporation | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same |
| MA49705A (fr) * | 2017-07-28 | 2021-03-31 | Yuhan Corp | Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation |
| EP3653622B1 (en) * | 2017-08-30 | 2022-12-28 | Shenzhen TargetRx, Inc. | Aminopyrimidine compound and composition comprising same and use thereof |
| CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
| CN108047207A (zh) * | 2018-01-30 | 2018-05-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用 |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| CN111349084B (zh) * | 2018-12-21 | 2022-11-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的氨基嘧啶类化合物 |
| WO2020174370A2 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| KR102318875B1 (ko) * | 2019-03-19 | 2021-11-01 | 보로노이 주식회사 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
| KR20210144844A (ko) | 2019-03-29 | 2021-11-30 | 아스트라제네카 아베 | 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙 |
| EA202193117A1 (ru) * | 2019-05-14 | 2022-02-11 | Янссен Байотек, Инк. | КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR |
| US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
| WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| TW202207940A (zh) | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
| EP4210702A1 (en) | 2020-09-14 | 2023-07-19 | JANSSEN Pharmaceutica NV | Fgfr inhibitor combination therapies |
| TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
| TWI867047B (zh) * | 2020-09-18 | 2024-12-21 | 南韓商沃若諾伊公司 | 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物 |
| KR20220085735A (ko) * | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| US20240262815A1 (en) * | 2021-05-07 | 2024-08-08 | Voronoi Inc. | Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient |
| JP2024519626A (ja) * | 2021-05-17 | 2024-05-21 | ボロノイ インコーポレイテッド | ヘテロアリール誘導体化合物およびその用途｛Ｈｅｔｅｒｏａｒｙｌ ｄｅｒｉｖａｔｉｖｅ ｃｏｍｐｏｕｎｄｓ，ａｎｄ ｕｓｅｓ ｔｈｅｒｅｏｆ｝ |
| WO2022253261A1 (zh) | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
| TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| EP4514793A1 (en) | 2022-04-28 | 2025-03-05 | Astrazeneca AB | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| TW202417040A (zh) | 2022-06-27 | 2024-05-01 | 瑞典商阿斯特捷利康公司 | 涉及用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑之組合 |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| AU2023371904A1 (en) * | 2022-11-03 | 2025-04-17 | Voronoi Inc. | Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| CN116655600B (zh) * | 2023-05-23 | 2025-08-22 | 江南大学 | 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途 |
| WO2025017409A1 (en) | 2023-07-14 | 2025-01-23 | Janssen Biotech, Inc. | Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026009146A1 (en) | 2024-07-01 | 2026-01-08 | Hetero Labs Limited | Benzimidazole compounds as egfr inhibitors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998040379A1 (en) | 1997-03-11 | 1998-09-17 | E.I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
| WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| CA2432131C (en) | 2000-12-21 | 2008-07-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| JP2005507423A (ja) | 2001-11-01 | 2005-03-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲン合成酵素キナーゼ３ベータ阻害剤（ｇｓｋ３阻害剤）としてのヘテロアリールアミン |
| PL377795A1 (pl) | 2002-11-28 | 2006-02-20 | Schering Aktiengesellschaft | Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| JP4428565B2 (ja) | 2004-10-05 | 2010-03-10 | 東京エレクトロン株式会社 | 処理液塗布装置 |
| WO2006044457A1 (en) | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| US20070072894A1 (en) | 2005-03-24 | 2007-03-29 | Kempf J V | Synthesis of pyrroloquinoline quinone (PQQ) |
| JP5007029B2 (ja) | 2005-07-13 | 2012-08-22 | Ｎｔｎ株式会社 | グリース組成物および該グリース封入転がり軸受 |
| JP2009506004A (ja) | 2005-08-25 | 2009-02-12 | エフ．ホフマン−ラ ロシュ アーゲー | ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール |
| JP2007117465A (ja) | 2005-10-28 | 2007-05-17 | Sharp Corp | 集塵器およびそれを備えた電気掃除機 |
| JP2009531943A (ja) | 2006-03-29 | 2009-09-03 | ケーティーフリーテル・カンパニー・リミテッド | デジタル処理装置及びこれを用いた付加サービス提供方法 |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| WO2007120593A1 (en) | 2006-04-12 | 2007-10-25 | Wyeth | Anilino-pyrimidine phenyl and benzothiophene analogs |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2361248B1 (en) * | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| CA2780892C (en) * | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| IN2013MN01519A (enExample) | 2011-02-25 | 2015-06-12 | Yuhan Corp | |
| ES2791308T3 (es) * | 2011-07-27 | 2020-11-03 | Astrazeneca Ab | Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer |
| CA2863517C (en) | 2012-01-20 | 2019-11-05 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
| WO2014040555A1 (zh) * | 2012-09-12 | 2014-03-20 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP3036231B1 (en) * | 2013-08-22 | 2020-02-26 | Jubilant Biosys Ltd. | Substituted pyrimidine compounds, compositions and medicinal applications thereof |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| WO2015188777A1 (en) * | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
-
2015
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 ES ES21171619T patent/ES3009926T3/es active Active
- 2015-10-13 HU HUE21171619A patent/HUE070874T2/hu unknown
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 EP EP24166947.2A patent/EP4421069B1/en active Active
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 PL PL21171619.6T patent/PL3929190T3/pl unknown
- 2015-10-13 US US14/881,930 patent/US9593098B2/en not_active Ceased
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 RS RS20250168A patent/RS66529B1/sr unknown
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 KR KR1020247013986A patent/KR20240074820A/ko active Pending
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/en active Active
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active Active
- 2015-10-13 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 LT LTEP21171619.6T patent/LT3929190T/lt unknown
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active Active
- 2015-10-13 FI FIEP21171619.6T patent/FI3929190T3/fi active
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/en not_active Ceased
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 EP EP21171619.6A patent/EP3929190B1/en active Active
- 2015-10-13 SM SM20250069T patent/SMT202500069T1/it unknown
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 HR HRP20250213TT patent/HRP20250213T1/hr unknown
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
- 2015-10-13 SM SM20210266T patent/SMT202100266T1/it unknown
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active Active
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 PT PT211716196T patent/PT3929190T/pt unknown
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Active
- 2015-10-13 DK DK21171619.6T patent/DK3929190T3/da active
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 SM SM20200059T patent/SMT202000059T1/it unknown
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/en active Active
- 2015-10-13 CA CA2962914A patent/CA2962914C/en active Active
- 2015-10-13 SI SI201532056T patent/SI3929190T1/sl unknown
- 2015-10-13 MX MX2020002168A patent/MX385942B/es unknown
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
-
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
-
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
-
2020
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
-
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown
-
2022
- 2022-11-18 US US18/057,062 patent/USRE50528E1/en active Active
-
2025
- 2025-05-28 NL NL301329C patent/NL301329I2/nl unknown
- 2025-06-02 HU HUS2500023C patent/HUS2500023I1/hu unknown
- 2025-06-03 FR FR25C1021C patent/FR25C1021I1/fr active Active
- 2025-06-03 LT LTPA2025522C patent/LTPA2025522I1/lt unknown
- 2025-06-05 NO NO2025025C patent/NO2025025I1/no unknown
- 2025-06-06 FI FIC20250023C patent/FIC20250023I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500023I1 (hu) | Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| IL258486B (en) | Compounds, compositions, and methods for modulating cftr | |
| DK3125927T3 (da) | Fremgangsmåder og sammensætninger til immunmodulering | |
| DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3283080T3 (da) | Sammensætninger til modulation af c9orf72-ekspression | |
| DK3119408T3 (da) | Overfladereageret calciumkarbonat til desensibilisering af tænder | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3307271T3 (da) | Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3143026T3 (da) | Forbindelser og sammensætninger til induktion af chondrogenese | |
| DK3148517T3 (da) | Sammensætninger og fremgangsmåder til fremme af knogledannelse | |
| DK3520591T3 (da) | Fremgangsmåde til spredning af gødningsmidler | |
| DK3114235T3 (da) | Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet | |
| DK3719021T3 (da) | Inhibitorer af adapterassocieret kinase 1, sammensætninger omfattende disse og fremgangsmåder til anvendelse deraf | |
| DK2910535T3 (da) | Sammensætning til anvendelse af ekspanderet perlit | |
| DK3113774T3 (da) | Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf | |
| DK3507282T3 (da) | Fremgangsmåde til fremstilling af indolcarboxamidforbindelser | |
| DK3097081T3 (da) | Fremgangsmåde til fremstilling af 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carbaldehyder og 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carboxylater | |
| DK3161136T3 (da) | Fremgangsmåde til berigelse af mikrovesikler |